| MB-107 | IND-14570; MB-107 | Phase 2 Clinical | National Heart, Lung And Blood Institute, National Institute Of Allergy And Infectious Diseases (Niaid), National Institute of Health, Islamabad, St. Jude Children'S Research Hospital | Immunologic Deficiency Syndromes; X-Linked Combined Immunodeficiency Diseases | Details |
| AWT-020 | AWT020; AWT-020; JS213; JS-213 | Phase 2 Clinical | Anwita Biosciences Inc | Autoimmune Diseases of the Nervous System; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Lung Neoplasms; Melanoma; Neoplasms; Solid tumours | Details |
| GI-101 | SIM-323; SIM323; SIM0323; GI-101 | Phase 2 Clinical | GI Innovation Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Neoplasms; Solid tumours; Uterine Cervical Neoplasms | Details |
| MB-501 | MB501; MB-501 | Phase 2 Clinical | Ascendis Pharma Inc | | Details |
| Pegenzileukin | IBI-127; THOR-707; SAR-444245 | Phase 2 Clinical | Synthorx Inc | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colorectal Neoplasms; Esophageal adenocarcinoma; Esophageal Squamous Cell Carcinoma; Head and Neck Neoplasms; Hodgkin Disease; Intestinal Neoplasms; Lymphoma, Large B-Cell, Diffuse; Melanoma; Mesothelioma; Multiple Myeloma; Neoplasm Metastasis; Oropharyngeal Neoplasms; Skin Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | Details |
| LTC-004 | LTC004; LTC-004 | Phase 2 Clinical | Leto Laboratories Co Ltd | Colorectal Neoplasms; Neoplasms; Pancreatic Neoplasms; Sarcoma; Solid tumours | Details |
| TransCon IL-2 β/γ | | Phase 2 Clinical | Ascendis Pharma A/S | Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Ovarian Neoplasms; Solid tumours | Details |
| TYF-IL-2Rg gene-modified autologous stem cells (Shenzhen Geno-Immune Medical Institute) | | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | X-Linked Combined Immunodeficiency Diseases | Details |
| Simlukafusp alfa | FAP-IL2v; RG-7461; aFAP-IL2v; RO-6874281; FAP-IL2v FP | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Breast Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Head and Neck Neoplasms; Melanoma; Solid tumours; Uterine Cervical Neoplasms | Details |
| BJ-001(Boji Biomedical Technology) | BJ-001 | Phase 1 Clinical | Boji Biomedical Technology (Hangzhou) Co Ltd | Communicable Diseases; Neoplasm Metastasis; Solid tumours | Details |
| ex vivo IL2RG stem cell-based gene therapy (Genethon/University College London/Hannover Medical School) | | Phase 1 Clinical | Genethon | Severe Combined Immunodeficiency | Details |
| PD 1-proIL-2v (Proviva Therapeutics) | PTX-912 | Phase 1 Clinical | Proviva Therapeutics Inc | Neoplasm Metastasis; Neoplasms; Solid tumours | Details |
| NL-201 (Neoleukin Therapeutics) | NL-201 | Phase 1 Clinical | Neoleukin Therapeutics Inc | | Details |
| Recombinant human interleukin 15(Beijing Kawin) | | Phase 1 Clinical | Beijing Kawin Technology Share-Holding Co Ltd | | Details |
